Grocery Outlet heads into its third-quarter report with a story that has flipped from repair to recovery in the span of two quarters. The question now is whether that recovery can survive its first real stress test. Management walked into this period knowing a multi-state cyclospora outbreak would shave roughly 100 basis points off comparable sales and push up produce shrink. It also planned to wind down the $20 million promotional bridge it used to hold customers while the opportunistic buying engine was rebuilt. Both moves land squarely in the quarter being reported on November 10 after the close.

The Street is braced for a soft quarter. Consensus calls for non-GAAP earnings of $0.14 per share on revenue of $1.17 billion. That revenue figure is essentially flat with a year ago, while earnings would fall well short of the $0.21 posted in the same quarter last year. The whisper number sits at $0.17, a meaningful step above consensus. That suggests the more engaged crowd thinks analysts have padded their models too heavily for the outbreak. For the full year, management lifted its earnings range to $0.51 to $0.55 and its sales outlook to $4.70 billion to $4.72 billion. Consensus earnings of $0.51 rest at the bottom of that band. The Street's $4.63 billion revenue estimate actually sits below management's raised range. Analysts are clearly not yet taking the company at its word, which leaves room for upside if the quarter holds together.

The core of the bull case is the opportunistic mix, the closeout and overrun deals that make the treasure-hunt format work. Last quarter, opportunistic mix had expanded more than 300 basis points and opportunistic comps had accelerated about 500 basis points from the start of the year. Grocery, the largest category, comped 3.5%, and the same playbook was being pushed into deli and frozen. This report should show whether that momentum carried forward under Paul Miller, the 25-year veteran who returned in June to run purchasing and merchandising. Management also pointed to new supplier acquisitions running 11% ahead year to date and dynamic routing in about 200 stores. Further gains in opportunistic mix would validate those claims. Signs that deal flow plateaued would undercut them.

Margins are the swing factor. Gross margin reached 30.2% last quarter, ahead of the company's outlook and up 60 basis points sequentially. Holding near that level despite cyclospora-related shrink would be a strong signal. It would suggest opportunistic buying is replacing promotional spend as a traffic driver rather than simply sitting alongside it. A sharper dip, or any hint that the promotional bridge must extend past the third quarter, would raise doubts about the margin path into 2027. That risk is sharper because competitors are leaning into price in the second half. Basket size is the other tell. Traffic has been growing, but basket was still down 2.1% last quarter. The turnaround cannot fully mature until shoppers start putting more in the cart.

The market has already rewarded the pivot. Shares have climbed nearly 19% since the last report while the S&P 500 slipped about 3%. At $13.23, the stock trades far above its 200-day average of $9.58, and its entire post-earnings range sits above the prior quarter's highs. It remains about 5% below the recent $13.99 peak, so this is not a breakout test. Sentiment has swung from modestly bearish heading into last quarter to modestly bullish now. Expectations, in other words, have firmed even if published estimates have not.

The decisive issue is whether the underlying comp trend, excluding cyclospora, kept improving while promotions tapered. If management can show that, and reaffirm or nudge up a full-year range the Street still underwrites cautiously, the recovery narrative stays intact. Commentary on the new CFO's priorities and the unresolved UGO review will matter at the margin. The real verdict, though, rests on opportunistic mix and gross margin.